A new class of anti-cancer drugs targeting the tyrosine kinase receptor ROR1 in CLL.Håkan Mellstedt, Ali Moshfegh, Mohammad Hojjat‐Farsangi et al.|Journal of Clinical Oncology|2015Cited by 4